A continuous high incidence or a large surge in cases in the early summer would imply a large benefit from an early second booster roll-out but optimal timing will largely depend on trends in infections ECDC says in the latest technical report on a second mRNA COVID-19 vaccine booster dose.
European Immunization Week is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunization for the general health and wellbeing of the European and wider population.
Since the onset of Russia’s aggression towards Ukraine on 24 February 2022, and as of 11 April 2022, more than 4 million Ukrainian people have fled to Poland, Hungary, Slovakia, Romania and the Republic of Moldova.
EMA and ECDC have reviewed currently available studies and epidemiological data to provide a common position for EU/EEA countries on the current need and potential benefit of a fourth dose (second booster dose) of mRNA COVID-19 vaccines.
ECDC and EMA’s COVID-19 task force (ETF) have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines (Pfizer’s Comirnaty and Moderna’s Spikevax) in the general population.
As of 10 February 2022, EU/EEA and EU-neighbouring countries reported 159 locally acquired human cases of West Nile virus infection, including 13 deaths, in 2021. The last case of this transmission season was reported by Greece in week 45.
According to the latest ECDC/WHO report on tuberculosis (TB) surveillance and monitoring in Europe, a sharp drop (24%) in reported tuberculosis cases between 2019 and 2020 was probably exacerbated by the COVID-19 pandemic, which hindered detection and reporting.
Displaced people from Ukraine hosted in reception centres should be offered free access to SARS-CoV-2 testing and vaccination for COVID-19. Additionally, protective measures are recommended by ECDC in the report Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the displacement of people from Ukraine, published on 18 March.
As of 30 January 2022, 70.9% of adolescents aged 15-17 years and 34.8% of 10-14 year-olds completed the primary course of COVID-19 vaccination, though with a broad range across EU/EEA countries. More than half of adolescents aged 10 to 17 in the EU/EEA have not yet completed a primary course.